Treatment of hemorrhagic dengue in the pediatric population: A systematic review
Título de la revista
ISSN de la revista
Título del volumen
Editorial Ciencias Medicas
Electronic database Medline, Embase, Cochrane Library and Lilacs were used to retrieve the clinical trials that will evaluate the various therapeutical options available for management of hemorrhagic dengue. Eight clinical studies were included. Supportive care and symptomatic treatment through hydration and aggressive fluid management, if hypotension develops in the course of disease, are the most important aids to improve survival. Treatment with corticosteroids such as methylprednisolone, hydrocortisone, carbazochorome sodium sulfonate (AC-17) and recombinant activated factor VII did not reduce mortality in children with hemorrhagic dengue. At present, no vaccine or effective antiviral treatment is available for the prevention or treatment of hemorrhagic dengue. © 2007 1999, Editorial Ciencias Médicas.
Adrenochrome , Antipyretic agent , Blood clotting factor 7a , Carbazochrome , Corticosteroid , Drug derivative , Hemostatic agent , Isotonic solution , Recombinant fviia , Recombinant protein , Bleeding , Child , Clinical trial (topic) , Colloid , Colombia , Crystalloid , Dengue , Disease management , Double blind procedure , Drug combination , Fluid therapy , Human , Multimodality cancer therapy , Oxygen therapy , Randomized controlled trial (topic) , Respiratory failure , Review , Shock , Statistics , Adrenal cortex hormones , Adrenochrome , Antipyretics , Child , Clinical trials as topic , Colloids , Colombia , Combined modality therapy , Dengue hemorrhagic fever , Disease management , Double-blind method , Drug therapy , Factor viia , Fluid therapy , Hemorrhage , Hemostatics , Humans , Isotonic solutions , Oxygen inhalation therapy , Randomized controlled trials as topic , Recombinant proteins , Respiratory insufficiency , Shock , Body fluids , Dengue hemorrhagic fever , Dengue shock syndrome , Treatment